WO2006059194A2 - Pharmaceutical sustained-release composition containing clozapine - Google Patents
Pharmaceutical sustained-release composition containing clozapine Download PDFInfo
- Publication number
- WO2006059194A2 WO2006059194A2 PCT/IB2005/003437 IB2005003437W WO2006059194A2 WO 2006059194 A2 WO2006059194 A2 WO 2006059194A2 IB 2005003437 W IB2005003437 W IB 2005003437W WO 2006059194 A2 WO2006059194 A2 WO 2006059194A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- clozapine
- composition according
- ethylcellulose
- cellulose
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Definitions
- This invention relates to a slow-release solid oral pharmaceutical composition containing clozapine, and its use in the treatment of psychotic disorders.
- [1,4] diazepine is classified as an "atypical" antipsychotic drug. This class of drug is used to treat complex, heterogeneous psychotic conditions of uncertain etiology, including schizophrenia and the associated schizoaffective disorders, from which 2% of the world population currently suffer.
- clozapine Compared with other neuroleptics, clozapine has the following specific characteristics: it acts as a broad-spectrum antagonist with differentiated receptor affinity, both in the dopaminergic system (greater affinity for the dopamine D4 receptor and lesser affinity, in decreasing order, for subtypes D2, Dl, D3 and D5) and outside that system (high affinity for serotonin and muscarinic receptors, and significant effects on the GABAergic and glutaminergic systems).
- clozapine The brain neurotransmitter receptor binding profile has made clozapine the drug of choice for the treatment of schizophrenic patients resistant or intolerant to the classic neuroleptics. Compared with those drugs, clozapine is practically devoid of extrapyramidal side effects, effective on both negative psychotic symptoms (apathy, blunted affect, social withdrawal, poverty of thought content) and positive symptoms (hallucinations, delirium and thought disorders), and able to reduce the risk of suicidal behaviour in schizophrenic patients.
- the major side effect of treatment with clozapine is agranulocytosis, which occurs in 1% of cases.
- evaluation of the risk/benefit ratio demonstrates that the frequency of suicide in drug-resistant schizophrenics not treated with clozapine is higher than mortality from agranulocytosis in schizophrenic patients treated with clozapine.
- the introduction of monitoring by systematic differential white blood cell count (conducted weekly for the first six months of treatment and fortnightly thereafter) has reduced the incidence of agranulocytosis to 0.38%.
- the absorption, distribution, metabolism and excretion profile of clozapine can be summed up as follows. After oral administration it is rapidly absorbed, and the peak concentration (Cmax) is reached in 2-4 hours (tmax). It has first-order absorption kinetics which remain linear in the plasma concentration range of 10-1000 ng/ml. The absorption rate is not affected by food. 97% of the drug bonds to plasma proteins. Before excretion it is rapidly metabolised by the liver microsomal enzymes, forming two metabolites: N-oxide and the N-desmethyl (active) derivative. During the first metabolic step, the bioavailability of clozapine is reduced by 50%. The amount of clozapine excreted in the urine and faeces is approximately 50% and 40% respectively.
- Clozapine is available on the market in immediate-release oral formulations consisting of 25 and 100 mg scored tablets. The treatment commences at 12.5 mg a day. If it proves tolerable it is gradually increased, by multiple administrations, until the optimum therapeutic dose range, generally between 300 and 600 mg a day, is reached within 15 days. In some cases, daily doses of up to 900 mg need to be reached.
- the subject of this invention is a solid oral slow-release "once a day" composition, which contains clozapine as active constituent and guarantees constant release of the drug for 24 hours, avoiding peaks and fluctuations in plasma levels.
- the composition takes the form of granules coated with polymers or cellulose derivatives, preferably chosen from among methyl-, ethyl- or propyl-cellulose, hydroxypropyl cellulose, hydroxyethylcellulose, hydroxypropyl methylcellulose, hydroxypropyl ethylcellulose, carboxymethylcellulose, cellulose acetate or phthalate, hydroxypropyl methylcellulose phthalate, cellulose acetate succinate, and ethylcellulose succinate.
- Ethylcellulose polymer is particularly preferred.
- the granules, of dimensions ranging between 500 and 1200 ⁇ m, can be distributed or incorporated in suitable oral pharmaceutical forms, preferably rigid gelatin capsules, tablets or sachets prepared by conventional techniques.
- the coated granules contain 85 to 95% (by weight), preferably 90-95%, of clozapine, and 1 to 3%, preferably 1.5 to 2% (by weight) of ethylcellulose.
- the unit dose of clozapine is between 12 and 900 mg.
- the composition according to the invention may contain pharmaceutically acceptable excipients such as lubricants (or gliding agents), diluents, dispersing agents or binders.
- the coated granules have the following percentage composition (by weight): clozapine 90%, polyethylene glycol (carbowax) 3%, polyvinylpyrrolidone 4.5%, ethylcellulose 1.7% and talc 0.8%.
- the daily dose can vary according to the patient's characteristics, but will generally be 400-600 mg qd.
- the coated granules can be prepared according to a process which basically comprises the following steps: mixing of active ingredient with binder solution; granulation of mixture; selection of granules of optimum size, for example by sieving; coating of granules by spraying with coating polymer and optionally adding a gliding agent; drying, and filling of final pharmaceutical form.
- the pharmaceutical composition according to the invention is indicated for the treatment of schizophrenia and associated disorders, especially the tendency to suicide in schizophrenic patients, psychosis, Parkinson's disease, and mood disorders in bipolar disorder.
- “Once a day” oral administration of the composition according to the invention presents various advantages, including: 1) maintenance of constant therapeutic blood levels of clozapine, 2) accuracy of dose and administration of treatment, 3) reduced risk of toxic effects, 4) improved therapeutic efficacy and patient compliance.
- Polyvinylpyrrolidone 1.25 Kg 0.312 Kg Polyethylene glycol 4000 (carbowax 4000) 0.83 Kg 0.206 Kg
- the polyethylene glycol 4000 is placed in a stainless steel container with a pneumatic agitator.
- the polyvinylpyrrolidone is then sprinkled onto it in small amounts, and maintained under constant agitation until completely solubilised.
- a precise quantity of clozapine is weighed and granulated in a granulator, using the previously prepared binder solution as aggregating agent.
- the wet granulate is forced through netting with 840 micron mesh and dried at 4O 0 C for 15 hours in a thermostated forced-air dryer.
- the granulate is then sieved through a 500 and 840 micron mesh sieve.
- the powder and the granules smaller than 500 microns are regranulated by the process described above, in this case using deionised water as aggregating agent.
- the granules are sieved with a 500 and 840 micron mesh sieve.
- the resulting granulate is weighed and placed in the stainless steel rack of a coating pan. To ensure sufficient rotation of the mass, the pan is rotated at approximately 12 rotations per minute.
- the granules are sprayed with binder solution using a spray device. Spraying is performed at intervals to allow better removal by suction of the steam generated by the water in the binder solution.
- the granulate is passed through netting with 1200 micron mesh and dried at 4O 0 C for 15 hours in a thermostated forced-air dryer. The granulate is then sieved through an 840 and 1200 micron mesh sieve.
- Acetone and alcohol are placed in a stainless steel container fitted with a pneumatic agitator.
- the ethylcellulose is then poured in slowly, and maintained under constant agitation until completely solubilised.
- the granulate obtained during the preceding stage is placed in a fluid bed and kept in suspension by a flow of filtered air.
- the coating solution is sprayed at intervals.
- small amounts of talc are scattered on the granulate in the intervals between spraying.
- the granulate is passed through netting with 1200 micron mesh and dried at 40 0 C for 15 hours in a thermostated forced-air dryer.
- the dried granules are sieved through an 840 and 1200 micron mesh sieve, collected in double polyethylene bags, and placed in hermetically sealed metal containers.
- the granules are automatically distributed between capsules by a machine programmed to fill hard gelatin capsules with predefined weights of granulate.
- the filled, closed capsules are collected in double polyethylene bags and placed in hermetically sealed metal containers.
- the release capacity of clozapine was tested on six 100 mg samples of formulation using a HCl solution at pH 1.1 (artificial gastric juice) in a continuous flow dissolver (25 ml/min at 37 0 C). Samples were taken from the dissolver for 24 hours, and the percentage release was calculated on the basis of the clozapine concentrations in the samples, determined by HPLC. The individual release percentages as well as the means, standard deviations and percentage coefficients of variation, are set out in the Table.
- EXAMPLE 3 Comparative pharmacokinetic profile of the new 25 mg clozapine "once a day” capsule formulation for single administration, and the reference commercial product Clozaril 25 mg tablets, half of which (12.5 mg) is administered twice a day
- a crossover study was conducted on 10 healthy volunteers, to whom a 25 mg clozapine "once a day" tablet was first administered one hour before breakfast (7.30 a.m.). After a suitable wash-out period, treatment with the reference clozapine was performed by administering it at the dose of 12.5 mg one hour before breakfast (7.30 a.m.) and one hour before the evening meal (7.30 p.m.).
- the figure contains graphs based on the mean plasma concentrations of clozapine determined by HPLC.
- the oral formulation according to the invention can be said to guarantee slow release of clozapine, so as to maintain constant levels of the drug in the plasma for at least 24 hours.
- This pharmacokinetic profile compared with that of the present immediate-release formulations of clozapine, prevents overdose, reduces the risk of some significant side effects and eliminates the need for repeated administrations during the day, leading to an improvement in therapeutic efficacy and patient compliance.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2004A002232 | 2004-11-19 | ||
IT002232A ITMI20042232A1 (en) | 2004-11-19 | 2004-11-19 | PHARMACEUTICAL COMPOSITION CONTAINING CLOZAPINE |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006059194A2 true WO2006059194A2 (en) | 2006-06-08 |
WO2006059194A3 WO2006059194A3 (en) | 2006-08-31 |
Family
ID=36565404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2005/003437 WO2006059194A2 (en) | 2004-11-19 | 2005-11-16 | Pharmaceutical sustained-release composition containing clozapine |
Country Status (2)
Country | Link |
---|---|
IT (1) | ITMI20042232A1 (en) |
WO (1) | WO2006059194A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018051292A1 (en) * | 2016-09-17 | 2018-03-22 | Intas Pharmaceuticals Ltd. | Extended release pharmaceutical composition of clozapine |
EP3520803A1 (en) | 2018-01-31 | 2019-08-07 | Zarodex Therapeutics Limited | Novel uses |
WO2019149862A1 (en) | 2018-01-31 | 2019-08-08 | Zarodex Therapeutics Limited | Clozapine for the treatment of a immunoglobulin driven b cell disease |
WO2019149863A1 (en) | 2018-01-31 | 2019-08-08 | Zarodex Therapeutics Limited | Clozapine for the treatment of ig-e driven b cell diseases |
WO2021019249A1 (en) | 2019-07-30 | 2021-02-04 | Zarodex Therapeutics Limited | Clozapine for use in treating pathogenic immunoglobulin driven b cell disease |
US11648207B1 (en) | 2021-12-15 | 2023-05-16 | Intas Pharmaceuticals Ltd. | Extended release pharmaceutical composition of Clozapine |
US11918590B2 (en) | 2021-12-15 | 2024-03-05 | Intas Pharmaceuticals Ltd. | Stable extended release pharmaceutical composition of clozapine |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5871778A (en) * | 1992-11-17 | 1999-02-16 | Yoshitomi Pharmaceutical Industries, Ltd. | Sustained release microsphere preparation containing antipsychotic drug |
US6197764B1 (en) * | 1997-11-26 | 2001-03-06 | Protarga, Inc. | Clozapine compositions and uses thereof |
-
2004
- 2004-11-19 IT IT002232A patent/ITMI20042232A1/en unknown
-
2005
- 2005-11-16 WO PCT/IB2005/003437 patent/WO2006059194A2/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5871778A (en) * | 1992-11-17 | 1999-02-16 | Yoshitomi Pharmaceutical Industries, Ltd. | Sustained release microsphere preparation containing antipsychotic drug |
US6197764B1 (en) * | 1997-11-26 | 2001-03-06 | Protarga, Inc. | Clozapine compositions and uses thereof |
Non-Patent Citations (1)
Title |
---|
VENKATESWARLU V ET AL: "Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles" JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 95, no. 3, 24 March 2004 (2004-03-24), pages 627-638, XP004496400 ISSN: 0168-3659 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018051292A1 (en) * | 2016-09-17 | 2018-03-22 | Intas Pharmaceuticals Ltd. | Extended release pharmaceutical composition of clozapine |
US11504336B2 (en) | 2016-09-17 | 2022-11-22 | Intas Pharmaceuticals Ltd. | Extended release pharmaceutical composition of clozapine |
US11833253B1 (en) | 2016-09-17 | 2023-12-05 | Intas Pharmaceuticals Ltd. | Extended release pharmaceutical composition of Clozapine |
EP3520803A1 (en) | 2018-01-31 | 2019-08-07 | Zarodex Therapeutics Limited | Novel uses |
WO2019149862A1 (en) | 2018-01-31 | 2019-08-08 | Zarodex Therapeutics Limited | Clozapine for the treatment of a immunoglobulin driven b cell disease |
WO2019149861A1 (en) | 2018-01-31 | 2019-08-08 | Zarodex Therapeutics Limited | Novel uses |
WO2019149863A1 (en) | 2018-01-31 | 2019-08-08 | Zarodex Therapeutics Limited | Clozapine for the treatment of ig-e driven b cell diseases |
WO2021019249A1 (en) | 2019-07-30 | 2021-02-04 | Zarodex Therapeutics Limited | Clozapine for use in treating pathogenic immunoglobulin driven b cell disease |
US11648207B1 (en) | 2021-12-15 | 2023-05-16 | Intas Pharmaceuticals Ltd. | Extended release pharmaceutical composition of Clozapine |
US11918590B2 (en) | 2021-12-15 | 2024-03-05 | Intas Pharmaceuticals Ltd. | Stable extended release pharmaceutical composition of clozapine |
Also Published As
Publication number | Publication date |
---|---|
WO2006059194A3 (en) | 2006-08-31 |
ITMI20042232A1 (en) | 2005-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101141508B1 (en) | Pantoprazole multiparticulate formulations | |
BR112021001345A2 (en) | multiparticulate cannabinoid formulations | |
WO2006059194A2 (en) | Pharmaceutical sustained-release composition containing clozapine | |
EP2838517B1 (en) | Orally available pharmaceutical formulation suitable for improved management of movement disorders | |
KR20160045053A (en) | Delayed release cysteamine bead formulation | |
US20030129244A1 (en) | Morphine sulfate microgranules, manufacturing process and pharmaceutical preparations | |
EP2090297A1 (en) | Formulations of flibanserin | |
JP6308938B2 (en) | Method for producing granular material | |
NL8302416A (en) | DELAYED MEDICINAL PRODUCT CONTAINING SULOCTIDIL. | |
EP2814465A1 (en) | Pharmaceutical formulation having improved stability | |
CN117462516A (en) | Novel sustained-release pellet, preparation method thereof and pellet tablet thereof | |
WO2023168316A1 (en) | Enteric coated dry powdered cannabinoid formulations | |
CN104257634A (en) | Ginkgo biloba extract pellet preparation with diphasic release performance | |
CN105902564B (en) | A kind of pharmaceutical composition and preparation method for treating hypertension | |
US9333170B2 (en) | Polyvalent polymeric matrix for modified release solid oral preparations and method of preparation thereof | |
EP3622948A1 (en) | Multilayered formulations with dual release rate of one or more active principles | |
PL198875B1 (en) | (E)-$g(a)-[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid arginyl charge-neutralization-complex, a process for its production and formulation | |
JP4754485B2 (en) | Coprecipitation active substance-containing particles | |
JP6163169B2 (en) | Use of modafinil in the treatment of cocaine addicts | |
EP1615627A1 (en) | Pharmaceutical composition containing levodopa and carbidopa | |
JP2007500225A (en) | Pharmaceutical composition for oral administration containing lithium carbonate | |
WO2002060448A1 (en) | Medicinal composition | |
Pranitha et al. | Formulation and Evaluation of Mebeverine Hydrochloride Sustained Release Capsules by Pelletization Technique | |
EP2749273B1 (en) | Solid oral preparation with modified release | |
CN104274410B (en) | A kind of pharmaceutical composition containing dabigatran etcxilate or its salt |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 05850665 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05850665 Country of ref document: EP Kind code of ref document: A2 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 5850665 Country of ref document: EP |